Refametinib

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP08334CAS No. ：923032-38-6;923032-37-5Purity：98%

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	923032-38-6;923032-37-5	Cat. No.	BCP08334
Name	Refametinib
Synonyms	RDEA-119;AY 86-9766;BAY 869766;
SMILES
Chemical Name
Formula	C19H20F3IN2O5S	M. Wt	572.34
Purity	98%	Storage	Store at 4-8°C
Description	in vitro: BAY 86-9766 exhibited potent antiproliferative activity in HCC cell lines with half-maximal inhibitory concentration values ranging from 33 to 762 nM. BAY 86-9766 was strongly synergistic with sorafenib in suppressing tumor cell proliferation and inhibiting phosphorylation of the extracellular signal-regulated kinase (ERK). in vivo: BAY 86-9766 prolonged survival in Hep3B xenografts, murine Hepa129 allografts, and MH3924A rat allografts. Additionally, tumor growth, ascites formation, and serum alpha-fetoprotein levels were reduced [1]. In a phase I/II study of patients with advanced solid tumors, refametinib was well tolerated at doses 100 mg daily. Rash was the most common TEAE. Subsequently, a phase II study enrolled seventy patients to evaluate refametinib in combination with sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC). Of sixty-five patients analyzed for efficacy per protocol, three (5%) had PR, and the median time-to-progression was